Withaferin A Suppresses Anti-apoptotic BCL2, Bcl-xL, XIAP and Survivin Genes in Cervical Carcinoma Cells
Purpose: To investigate the effect of withaferin A on the suppression of the anti-apoptotic genes, BCL2, Bcl-xL, XIAP and Survivin), in cervical carcinoma cells.
Methods: Annexin V-FITC/propidium iodide (PI) staining was used for the investigation of cell apoptosis. RNA RNeasy Kits was used to isolate RNA and Omniscript RT to reverse and transcribe the mRNA. Quantitative real-time polymerase chain reaction (qPCR) was performed using Taq PCR Master Mix Kit.
Results: Withaferin A (WFA) treatment reduced mRNA and protein levels of antiapoptotic genes in MCF-7 and HeLa cervical carcinoma cells. Suppression of BCL2, Bcl-xL, XIAP and Survivin induced a significant anti-proliferative effect. Treatment with WFA at a concentration of 20 μM, decreased cell viability and induced apoptosis. In MCF-7 cells, knockdown of BCL2, Bcl-xL, XIAP and Survivin caused 4-fold enhancement in apoptosis rate and 53 % decrease in cell viability.
Conclusion: WFA significantly leads to knockdown of antiapoptotic genes and is, therefore, a promising treatment strategy for cervical cancer.
Keywords: Anti-apoptotic genes, Cervical cancer, Apoptosis, Cell viability, BCL2, Bcl-xL, XIAP and Survivin
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.